The rise was driven by new generics and steady prices, with Eli Lilly's tirzepatide named in the market breakdown.
Recap by typeshit. Post by Facebook on Facebook.
The roundup also covers telehealth firms marketing off-label GLP-1s for addiction and a Treasury rule adding scrutiny to licensing deals with Chinese biotechs.
The GLP-1 Bridge pilot runs through 2027 and covers approved pills and shots for eligible Part D and Advantage enrollees, with no deductible.
KMOV shares an InvestigateTV+ piece on the national weight loss trend and what coverage your insurance plan might offer. Details are thin in the clip.
Le Figaro reports the tablet arrives in early November. Unlike the Wegovy injection, it won't be covered by France's public reimbursement system.
One UT San Antonio study found about 16% lower incidence in high-risk women with obesity. Discussant Rayjean Hung flagged biases that could inflate the effect.
Endpoints News
Endpoints News looks at big studies moving GLP-1s beyond diabetes and obesity into addiction, a use the public has speculated about for years.
Loading…